Loading…
Biotech that launched Rezdiffra, the first approved drug for MASH (fatty liver disease with fibrosis).
Biotech that launched Rezdiffra, the first approved drug for MASH (fatty liver disease with fibrosis).
Sells one drug, a daily pill meant for long-term use, so revenue builds as more patients are diagnosed and put on treatment. Most prescribers are liver and digestive specialists, and a key step is non-invasive testing that identifies who has the disease without a biopsy. It launched in 2024.
Moat: narrow (IP / patents, installed base). First-mover advantage as the only approved MASH therapy ahead of pipeline competitors.
Headquarters: West Conshohocken, Pennsylvania, United States · Founded: 1997 · Employees: 915
Size Madrigal Pharmaceuticals (MDGL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $9.28B, the 812th largest of 3,117 United States companies the cockpit tracks. Shares closed at $399.63 on 6 Nov 2026.
Performance Over six months the shares fell 21.6%, against +20.4% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 92.8% over the last twelve months (peer median +16.5%); the operating margin is -10.7% (peer median 15.3%).
Valuation It trades at 79.5× forward earnings against a peer median of 30.9× (most expensive of 14).
Short interest Short interest is 9.5% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.43B | $958M | $180M | $0 | $0 |
| Revenue growth | — | +432% | — | — | — |
| Gross profit | $1.30B | $901M | $173M | -$527,000 | -$467,000 |
| EBITDA | -$150M | -$299M | -$497M | -$380M | -$293M |
| Net income | -$155M | -$288M | -$466M | -$374M | -$295M |
| Free cash flow | -$169M | -$190M | -$457M | -$326M | -$225M |
| Capital expenditure | $11.6M | $3.47M | $6.46M | $1.48M | $217,000 |
| Total debt | $354M | $348M | $120M | $117M | $49.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals MDGL | $9.28B | -22% | +93% | -11% | 79.5× | n/a |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 11.9× | 0.1% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 28.9× | 5.9% |
| Inventiva IVA.PA | $912M | -29% | -100% | -307,063% | n/a | n/a |
| Altimmune ALT | $405M | -33% | +55% | -320,726% | n/a | n/a |
| Sagimet Biosciences SGMT | $693M | +28% | n/a | n/a | n/a | n/a |
| Viking Therapeutics VKTX | $3.42B | -17% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MDGL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.2% | +5.6% | 4th lowest of 21 |
| 6-month return | -21.6% | +20.4% | 2nd lowest of 21 |
| Distance from 52-week high | -35.0% | -13.6% | 3rd lowest of 21 |
| Revenue growth (TTM) | +92.8% | +16.5% | 2nd highest of 20 |
| Operating margin | -10.7% | 15.3% | 4th lowest of 19 |
| Forward P/E | 79.5× | 30.9× | most expensive of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 79.5× | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| Spyre Therapeutics SYRE | United States | $9.86B | +38% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $8.70B | -5% | +8% | 6% | 17.0× | 4.1% | +6.6% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.48B | -7% | +9% | 3% | 6.6× | -10.3% | +7.4% |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | n/a | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $8.19B | +22% | +24% | 17% | 29.2× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% | +12.6% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 15.6× | -6.1% | +9.3% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | n/a | -9.1% | +6.6% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 16.4× | 24.9% | +16.6% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | n/a | n/a | n/a |
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% | +18.1% |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% | +15.0% |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 32.0× | 20.0% | +9.4% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | n/a | 31.5% | +7.3% |
| Pharmaron Beijing 300759.SZ | China | $11.3B | +57% | +18% | 14% | 42.3× | n/a | n/a |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% | +7.1% |